02627.HK
Ab&B Bio Tech Co Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 29.32
−1.01%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +397.6%
- EBITDA
- +50.9%
- EBIT
- +45.8%
- Net income
- +39.1%
- EPS
- +38.9%
- Free cash flow
- +33.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2025